Increasing evidence suggests that the activation of the TGFβ1/SMAD signaling cascade in tumor cells promotes cell-cycle arrest, leading to the entry of tumor-propagating cancer cells into a quiescent state with decreased susceptibility to suffer cellular damage in response to therapeutic agents. This evidence concerns the gene TGFB1 and neoplasm.